WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/042029    International Application No.:    PCT/US2014/055816
Publication Date: 26.03.2015 International Filing Date: 16.09.2014
A61K 31/4166 (2006.01), A61K 31/535 (2006.01), C07D 233/86 (2006.01), C07D 413/10 (2006.01)
Applicants: GLAXOSMITHKLINE LLC [US/US]; Corporation Service Company 2711 Centerville Road Suite 400 Wilmington, New Castle, Delaware 19808 (US)
Inventors: GRESHOCK, Joel; (US).
BACHMAN, Kurtis Earl; (US).
BLACKMAN, Samuel Charles; (US)
Agent: FOSTER, Angela; (US)
Priority Data:
61/879,895 19.09.2013 US
Abstract: front page image
(EN)A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a PI3Kß inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or PI3Kß is beneficial, e.g., cancer.
(FR)La présente invention concerne une nouvelle combinaison comprenant l'inhibiteur du récepteur des androgènes, 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-méthylbenzamide ou son solvant ou son sel pharmaceutiquement acceptable, avec un inhibiteur de PI3Kß, l'acide 2-méthyl-1-{[2-méthyl-3-(trifluorométhyl)phényl]méthyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylique, ou son sel pharmaceutiquement acceptable, des compositions pharmaceutiques les comprenant et des procédés d'utilisation de ces combinaisons et compositions dans le traitement d'états pour lesquels l'inhibition du récepteur des androgènes et/ou du PI3Kß est bénéfique, par exemple le cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)